CVS Health Corp. has reportedly launched a new prescription drug plan that encourages customers to fill prescriptions at stores that do not sell tobacco products, like CVS. But according to some antitrust experts, the new incentives could raise antitrust concerns.
Reports say the plan charges prescription refill copays of up to $15 more when customers fill prescriptions at a store that sells tobacco products. Those stores include CVS rivals Walgreens, Rite-Aid and others.
While CVS says the new plan was the product of calls for a tobacco-free pharmacy network, experts say there could be legal trouble ahead as the program could unfairly steer customers towards CVS stores.
Former Federal Trade Commission executive David Balto, who is currently an antitrust attorney, says the pharmacy plan is concerning. “There’s no cost savings that comes about from limiting the network,” he said. “it’s really another effort to limit the ability of their rivals to effectively compete.”
The head of the Independent Pharmacy Alliance, John Giampolo, agrees. “It’s an unfair competitive practice,” he said.
Full content: Yahoo Finance
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Court Order Temporarily Halts U.S. Consumer Financial Protection Bureau Layoffs
Feb 16, 2025 by
CPI
Nokia Poised to Gain EU Approval for $2.3 Billion Infinera Acquisition
Feb 16, 2025 by
CPI
Turkey Fines Frito-Lay in Antitrust Crackdown
Feb 16, 2025 by
CPI
Advances Bill to Strengthen Antitrust Enforcement Through AI
Feb 16, 2025 by
CPI
Intel Faces Potential Breakup as Broadcom and TSMC Explore Deals
Feb 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon